997 resultados para 77DN_2005-08
Resumo:
Artikkelissa myös ote kirjasta Euroopan ensimmäinen naiseläinlääkäri, Vaasa 1964, Vaasa Oy:n kirjapaino
Resumo:
There is no registered treatment (ttr) for pts with mCRPC who have progressive disease during or shortly after docetaxel (doc). EGFR overexpression increases in prostate cancer during the course of the disease. We investigated efficacy and safety of the combination of the monoclonal EGFR antibody cetuximab (cet) and doc in pts with mCRPC who are doc-refractory. Methods: Pts with mCRPC progressing during or < 90 days after at least 12 weeks of doc were included. Ttr consisted of the same doc regimen as prior to progression (35mg/m2 d1,8,15 q4w or 75mg/m2 q3w) in combination with cet (400mg/m2 d1, then 250mg/m2 weekly). Primary endpoint was progression free survival (PFS) at 12 weeks defined as absence of PSA progression or progression of metastases (mets). Secondary endpoints included toxicity, PFS at 24 weeks, PSA response, response of measureable disease and overall survival. 35 pts were needed in a Simon's two stage optimal design with a power of 90% and a significance level of 5% in order to test PFS rate at 12 weeks of £10% vs ?30%. Results: 35 evaluable pts were enrolled at 15 Swiss centers between 7/08 and 9/09. Median follow up was 14.8 months. Confirmed PFS at 12 weeks was 34% (95%CI 19-52%), PFS at 24 weeks was 20% and overall survival was 12.0 months (95%CI 7.1 -15.6). 20% (7/35) had a confirmed decline in PSA ? 50% and 31% (11/35) had a confirmed PSA decline ? 30%. Of pts with measurable disease (n=24) PR, SD and PD at week 12 was 4%, 54% and 25%, respectively (17% not evaluable). 3/9 (33%) pts with PDduring last doc ttr before inclusion reached the primary endpoint compared to 7/18 (39%) with PR or SD to last doc. 54% of evaluable pts experienced grade 3 and 6% grade 4 toxicity. Discussion: The result of the primary endpoint was promising in this first trial to test cet in combination with doc in pts with docetaxel-refractory mCRPC. Because this goal was achieved in such a highly pretreated pts population it appears that inhibition of the EGFR pathway may play a more important and persistent role in the treatment of prostate cancer than perceived so far. Further research is therefore warranted. Disclosure: R. Cathomas: - Membership on advisory board for sanofi aventis (suisse) and Merck. S. Gillessen: - Membership in advisory board for Sanofi Aventis. All other authors have declared no conflicts of interest.
Resumo:
This phase I trial was designed to develop a new effective and well-tolerated regimen for patients with aggressive B cell lymphoma not eligible for front-line anthracycline-based chemotherapy or aggressive second-line treatment strategies. The combination of rituximab (375 mg/m(2) on day 1), bendamustine (70 mg/m(2) on days 1 and 2), and lenalidomide was tested with a dose escalation of lenalidomide at three dose levels (10, 15, or 20 mg/day) using a 3 + 3 design. Courses were repeated every 4 weeks. The recommended dose was defined as one level below the dose level identifying ≥2/6 patients with a dose-limiting toxicity (DLT) during the first cycle. Thirteen patients were eligible for analysis. Median age was 77 years. WHO performance status was 0 or 1 in 12 patients. The Charlson Comorbidity Index showed relevant comorbidities in all patients. Two DLTs occurred at the second dose level (15 mg/day) within the first cycle: one patient had prolonged grade 3 neutropenia, and one patient experienced grade 4 cardiac adverse event (myocardial infarction). Additional grade 3 and 4 toxicities were as follows: neutropenia (31 %), thrombocytopenia (23 %), cardiac toxicity (31 %), fatigue (15 %), and rash (15 %). The dose of lenalidomide of 10 mg/day was recommended for a subsequent phase II in combination with rituximab 375 mg/m(2) on day 1 and bendamustine 70 mg/m(2) on days 1 and 2.
Resumo:
A Catalunya, la presència de persones immigrades d'arribada recent ha significat un canvi substancial en les percepcions individuals i les representacions socials sobre la diversitat cultural. Aquest canvi ha resultat més destacat entre la població jove, en fase de construcció de la seva identitat, que ha hagut d'abordar les paradoxes del contacte entre cultures a partir d'estratègies de relació poc estructurades i planificades amb aquesta finalitat. La recerca KulTic¿08 ha explorat l'impacte de determinades paradoxes que es produeixen en el contacte amb altres realitats diferents a la pròpia i ha aplicat experimentalment un material en webquest, amb un enfocament socioafectiu i cognitiu i seguint els plantejaments pedagògics de l'aprenentatge cooperatiu.
Resumo:
A Catalunya, la presència de persones immigrades d'arribada recent ha significat un canvi substancial en les percepcions individuals i les representacions socials sobre la diversitat cultural. Aquest canvi ha resultat més destacat entre la població jove, en fase de construcció de la seva identitat, que ha hagut d'abordar les paradoxes del contacte entre cultures a partir d'estratègies de relació poc estructurades i planificades amb aquesta finalitat. La recerca KulTic¿08 ha explorat l'impacte de determinades paradoxes que es produeixen en el contacte amb altres realitats diferents a la pròpia i ha aplicat experimentalment un material en webquest, amb un enfocament socioafectiu i cognitiu i seguint els plantejaments pedagògics de l'aprenentatge cooperatiu.
Effect of Delay in Testing Asphalt Concrete Specimens for Marshall Stability, MLR-86-08, Draft, 1986
Resumo:
The Central Laboratory has been delaying the mix design testing of 2 1/2" X 4" Marshall specimens for stability, until the next day after molding. For example, if the mixes are made and samples molded on Friday a man would have to come in and work on Saturday to test these specimens. The reason for this is that the ASTM-01559 "Resistance to Plastic Flow of Bituminous Mixes Using Marshall Apparatus," states that "the specimens after being molded shall be carefully transferred to a smooth, flat surface and allowed to stand overnight at room temperature, before being weighed, measured and tested." The AASHTO procedure, AASHTO Designation T-245-82 "Resistance to Plastic Flow of Bituminous Mixtures using Marshall Apparatus," does not say when the specimens shall be tested for stability. The IDOT Lab. Specifications, Test Method No. Iowa 502-8 and test method No. Iowa 506-C "compacting asphaltic concrete by the Marshall Method" and "Resistance to Plastic Flow of Bituminous Mixtures Using the Marshall Apparatus," respectively, only state that the specimens shall be cooled before testing. Due to the above conflict in specifications, a number of mix samples were tested, in the Central Lab, for stability on different days. This should furnish enough information to allow us to change the procedure and to test for stability the same day molded, or be able to delay the testing for 3 days or more.
Resumo:
The specifications for concrete sand in Iowa have been used for many years with very good results. In several locations of the state, it is becoming more difficult to produce concrete sand consistently at a reasonable cost. Both ASTM and AASHTO have specifications for concrete sands that allow a finer, poorer graded sand than the Iowa specification. The ASTM and AASHTO specifications are based on the use of trial mix testing prior to construction. Iowa does not currently use the trial mix procedure.
Resumo:
Dr. Gilbert Y. Baladi of Michigan State University has developed a new device intended for reliable determination of asphalt concrete mechanical properties such as Poisson's ratio, resilient modulus, and indirect tensile strength. The device is the result of an effort to improve upon procedures and equipment currently available for evaluation of mechanical properties. A duplicate of this device was fabricated in the Iowa Department of Transportation, Materials Lab Machine Shop in 1989. This report details the results of an evaluation of the effectiveness of the device in testing Marshall specimens for indirect tensile strength as compared to results obtained with standard equipment described in AASHTO T-283. Conclusions of the report are: l. Results obtained with the Baladi device average 6 to 8 percent higher than those obtained with the standard device. 2. The standard device exhibited a slightly greater degree of precision than did the Baladi device. 3. The Baladi device is easier and quicker to use than the standard apparatus. 4. It may be possible to estimate indirect tensile strength from the stability/flow ratio by dividing by factors of 1.8 and 1.5 for 50 blow and 75 blow mixes respectively.
Resumo:
Crop and livestock summaries for the state of Iowa, produced by the Iowa Department of Agriculture. Previously Agri-News
Resumo:
Aquest TPT (Treball Pràctic Tutorat) esdevé la última etapa a realitzar per a la culminació dels estudis d’Enginyer Tècnic Forestal (especialitat en explotacions forestals). El TPT en qüestió és un Pla Tècnic de Gestió i Millora Forestal (PTGMF): Instrument d’Ordenació Forestal dels boscos públics i privats de Catalunya, gestionat pel Departament de Medi Ambient i Habitatge de la Generalitat de Catalunya mitjançant el Centre de la Propietat Forestal (CPF), on s’organitzen en el temps i l’espai totes les actuacions que es pretenen dur a terme en una zona d’estudi en concret (que ha de ser sempre major a 25 hectàrees). Un PTGMF consta de 3 parts diferenciades: - El PTGMF, pròpiament dit, com a document principal. - La cartografia (mapes de situació, de gestió i cadastral). - Els annexes (les fitxes descriptives de les unitats d’actuació i els resultats de l’inventari forestal).
Resumo:
Helsinki 1914
Resumo:
[Helsinki] 1915
